Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDL9WU)

Drug Name

AV-201 Drug Info

Synonyms

AAV (amino acid decarboxylase), Avigen; AAV (tyrosine hydroxylase), Avigen; AAV gene therapy (Parkinsons), Avigen; AAV vector (AADC), Avigen; AAV vector (TH), Avigen; AAV-hAADC-2; Gene therapy (PD), Avigen; Gene therapy (Parkinsons disease), Avigen; Gene therapy (L-aromatic amino acid decarboxylase), Avigen

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 2	[1]

Cross-matching ID

TTD Drug ID: DMDL9WU

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Aromatic-L-amino-acid decarboxylase (DDC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vitamin B6	DMDBZMV	Vitamin B6 deficiency	5B5D	Approved	[3]
Carbidopa	DMHRG8Q	Parkinson disease	8A00.0	Approved	[4]
Patrome	DM3H2U4	Parkinson disease	8A00.0	Phase 3	[5]
Benserazide	DMLU8NX	N. A.	N. A.	Phase 3	[4]
VY-AADC	DMPSBTL	Parkinson disease	8A00.0	Phase 2	[6]
GT-AADC	DM8N3OQ	Aromatic L-amino acid decarboxylase deficiency	5C59.00	Phase 2	[7]
PTC-AADC	DM9ZHE3	Aromatic L-amino acid decarboxylase deficiency	5C59.00	Phase 2	[8]
ProSavin	DMJ42E6	Parkinson disease	8A00.0	Phase 1/2	[9]
OXB-102	DMXF9DM	Parkinson disease	8A00.0	Phase 1/2	[10]
VY-AADC01	DM0N71R	Parkinson disease	8A00.0	Phase 1	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aromatic-L-amino-acid decarboxylase (DDC)	TTN451K	DDC_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of Genzyme.
2	UCSF report
3	Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Aug 5;137B(1):1-4.
4	Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
5	The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000 Nov;6(11):4365-72.
6	Clinical pipeline report, company report or official report of Voyager Therapeutics.
7	Clinical pipeline report, company report or official report of PTC Therapeutics.
8	ClinicalTrials.gov (NCT04903288) An Open-Label Trial to Address the Safety of the SmartFlow MR-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects. U.S.National Institutes of Health.
9	Clinical pipeline report, company report or official report of Oxford BioMedica.
10	Clinical pipeline report, company report or official report of Oxford BioMedica.
11	Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial. Neurology. 2022 Jan 4;98(1):e40-e50.